Trulieve Cannabis (TRLV) EBITDA Margin (2020 - 2026)

Trulieve Cannabis (TRLV) has reported EBITDA Margin for 7 consecutive years, with 12.46% the latest figure, recorded in Q1 2026.

• In Q1 2026, EBITDA Margin rose 127.0% year-over-year to 12.46%; the TTM figure through Mar 2026 stood at 12.47% (up 530.0% YoY), while the FY2025 annual figure was 14.28%, up 171.0% from the prior year.
• EBITDA Margin came in at 12.46% for Q1 2026 at Trulieve Cannabis, up from 5.22% in the prior quarter.
• The five-year high for EBITDA Margin was 19.62% in Q2 2022, with the low at 103.37% in Q2 2023.
• Average EBITDA Margin over 5 years is 3.42%, with a median of 12.46% recorded in 2026.
• Across the five-year window, EBITDA Margin sank 12299 bps in 2023 and jumped 11977 bps in 2024, its largest moves.
• Year by year, EBITDA Margin stood at 0.67% in 2022, then jumped by 1514 bps to 9.51% in 2023, then plunged by 95 bps to 0.43% in 2024, then surged by 1101 bps to 5.22% in 2025, then surged by 139 bps to 12.46% in 2026.
• According to Business Quant data, EBITDA Margin over the past three periods registered 12.46%, 5.22%, and 14.66% for Q1 2026, Q4 2025, and Q3 2025 respectively.